DPP-4 inhibitor treatment: β-cell response but not HbA(1c) reduction is dependent on the duration of diabetes

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by enhancing insulin and suppressing glucagon secretion. Since T2DM is associated with progressive loss of β-cell function, we hypothesized that the DPP-4 inhibitor action to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozlovski, Plamen, Bhosekar, Vaishali, Foley, James E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383079/
https://www.ncbi.nlm.nih.gov/pubmed/28408838
http://dx.doi.org/10.2147/VHRM.S125850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383079/
https://www.ncbi.nlm.nih.gov/pubmed/28408838
http://dx.doi.org/10.2147/VHRM.S125850

Ejemplares similares